Myriad Genetics, Inc.
MYGN
$6.10
$0.437.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -154.64% | 56.78% | 51.65% | 57.73% | 37.47% |
| Total Depreciation and Amortization | 8.47% | 14.10% | 8.90% | 12.23% | -8.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 514.88% | 47.01% | 61.56% | -13.45% | 12.61% |
| Change in Net Operating Assets | -29.78% | -249.51% | -301.48% | -178.23% | -161.12% |
| Cash from Operations | 75.65% | 93.35% | 92.16% | -10.24% | -109.95% |
| Capital Expenditure | 53.66% | 62.07% | 69.94% | 62.54% | 56.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -250.00% | -111.75% | -101.79% | -101.05% | -96.88% |
| Cash from Investing | 51.43% | -33.67% | -137.30% | -316.87% | -226.13% |
| Total Debt Issued | -33.33% | -28.57% | 50.00% | 250.00% | 200.00% |
| Total Debt Repaid | 49.83% | 19.84% | -198.26% | -140,300.00% | -- |
| Issuance of Common Stock | -95.58% | -95.23% | -95.23% | 5,175.00% | 3,736.36% |
| Repurchase of Common Stock | 22.48% | 16.67% | -52.27% | -55.68% | -24.04% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 97.83% | 94.12% |
| Cash from Financing | -86.55% | -89.93% | -104.84% | 288.93% | 306.47% |
| Foreign Exchange rate Adjustments | 185.71% | 75.00% | -266.67% | -33.33% | -300.00% |
| Miscellaneous Cash Flow Adjustments | 200.00% | -- | -- | -- | -- |
| Net Change in Cash | -52.17% | -110.82% | -138.93% | 196.50% | -276.92% |